What does it take to complete a third of a global Phase III lung cancer study faster than the rest of the world? Contracted by a Korean biotech to run a full-service trial for a biosimilar in non-small cell lung cancer, Palleos faced massive data volumes, strict Sponsor SOPs, and a penalty system for missed milestones.
Instead of just managing the workload, we outran it. By implementing a dedicated back-up CRA team (oncology experts on standby), adaptive monitoring schedules, and site-by-site data extrapolation, we achieved 100% recruitment of 254 patients in just 8 months — 7 months ahead of the global target. The study successfully passed an EMA inspection.
Download the full case study to see how proactive risk management accelerates timelines in competitive oncology trials.
Need clinical research solutions for your next trial? Contact us at info@palleos.com.
